ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer | Zendy

Franklin C. Harwood | Zendy; Ramon I. Klein Geltink | Zendy; Brendan P. O’Hara | Zendy; Monica Cardone | Zendy; Laura J. Janke | Zendy; David Finkelstein | Zendy; Igor Entin | Zendy; Leena Paul | Zendy; Peter J. Houghton | Zendy; Gerard C. Grosveld | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer

Author(s) -

Franklin C. Harwood,

Ramon I. Klein Geltink,

Brendan P. O’Hara,

Monica Cardone,

Laura J. Janke,

David Finkelstein,

Igor Entin,

Leena Paul,

Peter J. Houghton,

Gerard C. Grosveld

Publication year - 2018

Publication title -

science advances

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.928

H-Index - 146

ISSN - 2375-2548

DOI - 10.1126/sciadv.aar3938

Subject(s) - pi3k/akt/mtor pathway , transcription factor , discovery and development of mtor inhibitors , rptor , cancer research , component (thermodynamics) , cancer , sirolimus , mechanistic target of rapamycin , transcription (linguistics) , microbiology and biotechnology , biology , chemistry , computational biology , signal transduction , genetics , biochemistry , physics , gene , linguistics , philosophy , thermodynamics

A novel mTOR complex assembled by the ETS transcription factor ETV7 contributes to rapamycin resistance in cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research